Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy.
作者信息
Libert Diane, Yuan Constance M, Masih Katherine E, Galera Pallavi, Salem Dalia, Shalabi Haneen, Yates Bonnie, Delbrook Cindy, Shern Jack F, Fry Terry J, Khan Javed, Stetler-Stevenson Maryalice, Shah Nirali N
机构信息
Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda, MD, USA.
Laboratory of Pathology, CCR, NCI, NIH, Bethesda, MD, USA.
出版信息
Leukemia. 2020 Nov;34(11):3064-3069. doi: 10.1038/s41375-020-0760-x. Epub 2020 Feb 26.
Abstract
摘要
相似文献
1
Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy.CD19靶向治疗后小儿B细胞恶性肿瘤中CD19表面表达的系列评估。
Leukemia. 2020 Nov;34(11):3064-3069. doi: 10.1038/s41375-020-0760-x. Epub 2020 Feb 26.
2
Editorial: Mouse Models of B Cell Malignancies.社论：B细胞恶性肿瘤的小鼠模型
Front Immunol. 2021 Oct 28;12:789901. doi: 10.3389/fimmu.2021.789901. eCollection 2021.
3
CD19 as an attractive target for antibody-based therapy.CD19 作为抗体治疗的一个有吸引力的靶点。
MAbs. 2012 Sep-Oct;4(5):571-7. doi: 10.4161/mabs.21338. Epub 2012 Jul 23.
4
Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies.肿瘤特异性活性氧物种加速器改善嵌合抗原受体 T 细胞疗法在 B 细胞恶性肿瘤中的应用。
Int J Mol Sci. 2019 May 18;20(10):2469. doi: 10.3390/ijms20102469.
5
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.免疫肿瘤学概念：用靶向 CD19 的双特异性 T 细胞衔接器疗法治疗 B 细胞恶性肿瘤。
Ann Hematol. 2020 Oct;99(10):2215-2229. doi: 10.1007/s00277-020-04221-0. Epub 2020 Aug 27.
6
Generation of CD19-Targeted Chimeric Antigen Receptor T Cells.生成靶向 CD19 的嵌合抗原受体 T 细胞。
Arch Iran Med. 2019 Jan 1;22(1):7-10.
7
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.用表达抗 CD19 嵌合抗原受体的 T 细胞治疗 B 细胞癌。
Nat Rev Clin Oncol. 2013 May;10(5):267-76. doi: 10.1038/nrclinonc.2013.46. Epub 2013 Apr 2.
8
[Adoptive immunotherapy utilizing anti-CD19 chimeric antigen receptor T-cells for B-cell malignancies].利用抗CD19嵌合抗原受体T细胞治疗B细胞恶性肿瘤的过继性免疫疗法
Rinsho Ketsueki. 2016;57(11):2365-2372. doi: 10.11406/rinketsu.57.2365.
9
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.一种糖基化工程化的抗 CD19 抗体，具有体外强大的抗体依赖性细胞细胞毒性活性和体内淋巴瘤生长抑制活性。
Br J Haematol. 2011 Nov;155(4):426-37. doi: 10.1111/j.1365-2141.2011.08857.x. Epub 2011 Sep 9.
10
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression.靶向急性 B 细胞白血病的嵌合抗原受体 T 细胞，不受 CD19 表达的影响。
Leukemia. 2021 Jan;35(1):75-89. doi: 10.1038/s41375-020-0792-2. Epub 2020 Mar 24.
引用本文的文献
1
IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies.IKAROS水平与B细胞恶性肿瘤的CD19和CD22靶向治疗中的抗原逃逸相关。
Nat Commun. 2025 Apr 23;16(1):3800. doi: 10.1038/s41467-025-58868-2.
2
TCR/CD3-based synthetic antigen receptors (TCC) convey superior antigen sensitivity combined with high fidelity of activation.基于 TCR/CD3 的合成抗原受体（TCR）传递了更高的抗原敏感性，同时具有高保真的激活特性。
Sci Adv. 2024 Sep 6;10(36):eadj4632. doi: 10.1126/sciadv.adj4632. Epub 2024 Sep 4.
3
Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients.成人复发性急性淋巴细胞白血病的治疗。
Curr Treat Options Oncol. 2024 Aug;25(8):993-1010. doi: 10.1007/s11864-024-01213-4. Epub 2024 Jun 25.
4
The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going?嵌合抗原受体（CAR）T细胞疗法在儿科患者中的应用：我们从何而来，如今身处何方，又将走向何处？
Clin Hematol Int. 2024 Mar 13;6(1):96-115. doi: 10.46989/001c.94386. eCollection 2024.
5
Standardization of flow cytometric detection of antigen expression.流式细胞术检测抗原表达的标准化。
Cytometry B Clin Cytom. 2024 Jan;106(1):25-34. doi: 10.1002/cyto.b.22155. Epub 2024 Jan 12.
6
A stem cell epigenome is associated with primary nonresponse to CD19 CAR T cells in pediatric acute lymphoblastic leukemia.干细胞表观基因组与儿童急性淋巴细胞白血病对 CD19 CAR T 细胞的原发性无反应相关。
Blood Adv. 2023 Aug 8;7(15):4218-4232. doi: 10.1182/bloodadvances.2022008977.
7
Blinatumomab Prior to CAR-T Cell Therapy-A Treatment Option Worth Consideration for High Disease Burden.嵌合抗原受体T细胞疗法前使用博纳吐单抗——高疾病负担下值得考虑的一种治疗选择
Biomedicines. 2022 Nov 13;10(11):2915. doi: 10.3390/biomedicines10112915.
8
Reliable Flow-Cytometric Approach for Minimal Residual Disease Monitoring in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia after CD19-Targeted Therapy.用于监测B细胞前体急性淋巴细胞白血病患者CD19靶向治疗后微小残留病的可靠流式细胞术方法
Cancers (Basel). 2022 Nov 5;14(21):5445. doi: 10.3390/cancers14215445.
9
Emerging frontiers in immuno- and gene therapy for cancer.癌症的免疫和基因治疗新兴前沿。
Cytotherapy. 2023 Jan;25(1):20-32. doi: 10.1016/j.jcyt.2022.10.002. Epub 2022 Oct 22.
10
The CD19neg needle in the haystack.
Blood. 2022 Jul 7;140(1):4-6. doi: 10.1182/blood.2022016335.
Zotero 插件